9.4834
1.04%
-0.1066
전일 마감가:
$9.59
열려 있는:
$9.62
하루 거래량:
195.19K
Relative Volume:
0.08
시가총액:
$2.84B
수익:
$455.66M
순이익/손실:
$-119.54M
주가수익비율:
-14.82
EPS:
-0.64
순현금흐름:
$-48.10M
1주 성능:
-5.95%
1개월 성능:
-20.98%
6개월 성능:
-4.24%
1년 성능:
-11.80%
아미쿠스 테라 Stock (FOLD) Company Profile
명칭
Amicus Therapeutics Inc
전화
(609) 662-2000
주소
47 HULFISH STREET, PRINCETON, NJ
FOLD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
FOLD | 9.48 | 2.84B | 455.66M | -119.54M | -48.10M | -0.64 |
VRTX | 448.44 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 745.09 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.64 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.23 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
아미쿠스 테라 Stock (FOLD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-09-06 | 개시 | Jefferies | Buy |
2024-05-30 | 개시 | Wells Fargo | Overweight |
2024-05-14 | 업그레이드 | Guggenheim | Neutral → Buy |
2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
2022-04-13 | 재개 | Goldman | Neutral |
2022-01-14 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2021-11-15 | 업그레이드 | Stifel | Hold → Buy |
2021-09-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-07-19 | 재개 | BTIG Research | Buy |
2021-05-27 | 개시 | Needham | Hold |
2021-05-21 | 개시 | UBS | Buy |
2021-04-14 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2021-03-02 | 개시 | Stifel | Hold |
2021-02-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-12-28 | 재개 | Cantor Fitzgerald | Overweight |
2020-12-10 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-11-11 | 개시 | Berenberg | Hold |
2020-06-17 | 개시 | BTIG Research | Buy |
2020-02-04 | 재개 | Cantor Fitzgerald | Overweight |
2019-11-12 | 재확인 | H.C. Wainwright | Buy |
2019-06-17 | 개시 | H.C. Wainwright | Buy |
2019-06-05 | 재확인 | Cantor Fitzgerald | Overweight |
2019-04-05 | 개시 | Janney | Buy |
2019-01-30 | 개시 | Cantor Fitzgerald | Overweight |
2018-10-29 | 개시 | Citigroup | Neutral |
2018-08-17 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2017-10-06 | 재개 | Goldman | Neutral |
2017-09-13 | 재확인 | Chardan Capital Markets | Buy |
2017-08-10 | 재확인 | Chardan Capital Markets | Buy |
2017-01-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2016-05-18 | 개시 | BofA/Merrill | Buy |
2016-04-14 | 개시 | Robert W. Baird | Neutral |
2016-04-12 | 재확인 | Chardan Capital Markets | Buy |
2015-09-16 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2015-06-16 | 재확인 | Chardan Capital Markets | Buy |
모두보기
아미쿠스 테라 주식(FOLD)의 최신 뉴스
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap DownShould You Sell? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc - GuruFocus.com
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Acquires Shares in Amic - GuruFocus.com
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated - MSN
Avoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics Inc - GuruFocus.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLP - MarketBeat
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics - Benzinga
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts - Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) - Benzinga
Amicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $17.00 - MarketBeat
FOLDAmicus Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden - Simply Wall St
Fiera Capital Corp Reduces Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Amicu - GuruFocus.com
Amicus Therapeutics CEO Campbell sells $98,800 in stock - Investing.com India
Amicus Therapeutics CEO Campbell sells $98,800 in stock By Investing.com - Investing.com Australia
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Downgraded by StockNews.com to Hold - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Guggenheim - MarketBeat
Teva’s Galafold generic for Fabry disease may be available in US - Fabry Disease News
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock - Yahoo Finance
Needham & Company LLC Reiterates Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Call Transcript - Insider Monkey
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights - Benzinga
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings - Yahoo Finance
Earnings call: Amicus Therapeutics reports robust Q3 growth, raises guidance - Investing.com India
Earnings call: Amicus Therapeutics reports robust Q3 growth, raises guidance By Investing.com - Investing.com Canada
Amicus Therapeutics Q3 2024 Earnings Preview - MSN
Old West Investment Management LLC Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings: Revenue Surges - GuruFocus.com
Amicus Therapeutics: Q3 Earnings Snapshot - San Antonio Express-News
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Bradley Campbell sells $85,959 in stock By Investing.com - Investing.com Canada
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know - MSN
Allspring Global Investments Holdings LLC Has $172,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - Defense World
Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Cradle of Cures - Site Selection Magazine
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewswire
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - MarketBeat
abrdn plc Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com - Defense World
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amicus Therapeutics (FOLD) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
아미쿠스 테라 (FOLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):